MedTrace Logo

Clinical Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy for Operable Locally Advanced Head and Neck Squamous Cell Carcinoma

NCT04922450 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2021-06-10

No results posted yet for this study

Summary

In this single-arm study, pathologically confirmed advanced head and neck squamous cell carcinoma will be enrolled to investigate the efficacy and safety of Camrelizumab in combination With albumin paclitaxel and cisplatin.

Conditions

Interventions

DRUG

PD-1 inhibitor

Intravenous administration of SHR1210 (200mg/3weeks)

DRUG

Albumin Paclitaxel

Albumin Paclitaxel(260mg/m²),every 3 weeks

DRUG

Cisplatin

Cisplatin（80mg/m²）, every 3 weeks

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    collaborator INDUSTRY

  • Hunan Cancer Hospital

    lead OTHER

Principal Investigators

  • Yaqian Han · Hunan Cancer Hospital

  • Wenxiao Huang · Hunan Cancer Hospital

  • Hui Wang · Hunan Cancer Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-20
Primary Completion
2023-01-20
Completion
2023-01-20

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04922450 on ClinicalTrials.gov